Advanced Oncotherapy plc

Advanced Oncotherapy plc, alongside its affiliated entities, specializes in the development, production, and distribution of sophisticated proton-based radiotherapy systems aimed at treating cancer. A key initiative for the company involves advancing its Linac Image Guided Hadron Technology (LIGHT) system, an innovative proton therapy solution specifically engineered for oncology applications. Furthermore, the firm oversees the management of properties within the healthcare sector. Its operational reach extends across the United Kingdom, Switzerland, and the United States. Established in 1994, the company was initially incorporated as CareCapital Group plc before adopting its current name, Advanced Oncotherapy PLC, in September 2012. Its principal offices are located in London, UK.

Advanced Oncotherapy plc trades as AVO.L on LSE. The company is classified in Healthcare / Medical - Devices and reports in GBP.

The current profile places the business in Medical - Devices. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows £0 of revenue and -£35.25M of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

Advanced Oncotherapy plc can be compared against peers such as Belluscura plc, BiVictriX Therapeutics Plc, Celadon Pharmaceuticals Plc, Cel AI PLC, Induction Healthcare Group PLC, Kanabo Group Plc.

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of £9.50M, beta of 0.06, and return on equity of -57.4%.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

AVO.L currently shows total debt of £53.36M and beta of 0.06. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.avoplc.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.